Summit Therapeutics

Summit Therapeutics, Inc. a biopharmaceutical company, which discovers, develops, and commercializes medicines to treat infectious diseases. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Menlo Park, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Summit Therapeutics reports strong financials and strategic Akeso partnership

Summit Therapeutics showcased strong financials, promising clinical trial results, and a strategic partnership with Akeso for ivonescimab, positioning the company for growth.
While facing challenges around licensing agreements and international trial data acceptance, Summit's focus on oncology and global collaborations presents opportunities for future success.
With a solid financial foundation, innovative pipeline, and strategic vision, Summit is well-positioned to navigate challenges, capitalize on opportunities, and drive value for stakeholders.

Summit Therapeutics secures $5B deal for ivonescimab, shifts to oncology

Summit Therapeutics made a strategic move with a $5 billion transaction for ivonescimab, signaling a shift towards oncology-focused R&D.
While challenges exist in transitioning away from anti-infectives, Summit's strong financial position and Phase III progress offer promising opportunities.
The company's commitment to innovative therapies and strategic partnerships sets the stage for potential growth and market success.

Summit Therapeutics reports stable finances and progress in Phase III trials

Summit Therapeutics showcased resilience with a strong cash position despite reporting a net loss in Q2 2023.
The company's progress in Phase III trials and positive patient response data offer promise for future growth.
While facing challenges in trial execution and financial pressures, Summit has opportunities to advance its pipeline and attract investor support.

Summit Therapeutics advances ivonescimab in Q3 with strong financials

Summit Therapeutics is making significant strides in advancing ivonescimab for solid tumors, supported by strong financials and strategic partnerships. While facing challenges in differentiation and competitive landscape, the company is well-positioned to seize opportunities for growth and innovation. With a focus on operational excellence and clinical trial progress, Summit remains poised for future success.

Summit Therapeutics excels in Q4 with Ivonescimab progress and challenges

Summit Therapeutics showcased strong performance and financial stability, driven by advancements in Ivonescimab's trials and partnerships.
While facing challenges such as upcoming regulatory actions and timeline constraints, the company remains poised to leverage opportunities for market differentiation and growth.

Summit Therapeutics advances ivonescimab in oncology, eyes Phase III data

Summit Therapeutics made significant progress in Q1 2024, bolstered by strong financials and strategic collaborations. The company's focus on ivonescimab's potential in oncology, along with upcoming data releases, positions it for future success. Managing R&D expenses and leveraging key partnerships will be critical for sustained growth.

Summit Therapeutics advances ivonescimab with strong financial backing and collaborations

Summit Therapeutics made significant progress in clinical trials and regulatory milestones for ivonescimab, supported by strong financials and strategic collaborations.
While facing challenges in data disclosure and operational management, the company has opportunities to drive growth through further trial success and partnerships.
Overall, Summit Therapeutics is well-positioned to capitalize on its strengths and navigate challenges to unlock future opportunities in the competitive biopharmaceutical landscape.
Investors should monitor the company's continued progress in trials, partnerships, and financial management for insights into its long-term growth potential.

Summit Therapeutics advances ivonescimab with strong financial backing and global trials

Summit Therapeutics demonstrated strong performance in advancing ivonescimab, supported by robust financial management and operational efficiency.
While facing challenges in regulatory uncertainties and managing expenses, the company has opportunities to leverage positive trial outcomes and strategic expansions.
Overall, Summit Therapeutics' progress with ivonescimab presents a promising outlook for accelerated development and market growth in diverse tumor settings.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics stock is up a remarkable 700% this year.

Has Summit Therapeutics Stock Already Peaked?

Summit Therapeutics is having a great year, and it could realize revenue soon. Its partner Akeso could keep its pipeline packed with late-stage programs.

Is Summit Therapeutics Stock a Buy?

Intuitive Machines Inc

Intuitive Machines secured a NASA contract worth up to $4.82 billion, positioning it as a leader in the emerging trillion-dollar space industry. Summit Therapeutics' ivonescimab outperformed the world's best-selling cancer drug in a recent clinical trial.

2 High-Potential Growth Stocks You Shouldn't Overlook

Viking Therapeutics

Viking Therapeutics and Summit Therapeutics both have potential blockbusters on their hands. Their shares have soared this year on the back of strong clinical progress.

Better Rising Biotech: Viking Therapeutics vs. Summit Therapeutics

Instil Bio

Summit Therapeutics' stock is way up in response to clinical trial results that suggest the cancer therapy it's developing could become the standard of care for lots of patients. Instil Bio stock soared because it's developing a bispecific antibody similar to the candidate that pushed up Summit Therapeutics.

2 Stocks Up Over 700% in 2024 That Could Soar Even Further

This biotech has skyrocketed in value since January. It owes its performance to a potential billion-dollar cancer drug.

This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy?

Merck

Summit Therapeutics' ivonescimab shows improved efficacy over Merck's Keytruda in Phase III trials, targeting both PD-1 and VEGF, potentially expanding the PD-1 inhibitor market. Despite risks, Summit's promising data and significant insider investment suggest a speculative buy, with potential for major upside if FDA approval is achieved. Ivonescimab's dual mechanism could disrupt the oncology market, similar to Regeneron's Eylea, positioning Summit for substantial growth if it captures market share.

Summit Therapeutics Bests Merck's Top Selling Drug In Phase III Trial

Positive results for Summit's cancer drug in a head-to-head study against Keytruda have caused its stock to soar. Investors have great expectations for Summit's lead candidate.

Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year?

Summit's cancer drug ivonescimab outperformed Keytruda in a recent clinical trial. The success of that trial led to a massive rally for the healthcare stock.

This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.

A bispecific antibody Summit Therapeutics licensed from Akeso outperformed the world's best-selling cancer therapy. In a phase 3 trial, treatment with ivonescimab reduced patients' risk of disease progression by 49% compared to Keytruda.

Here's Why Everyone's Talking About Summit Therapeutics

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for the novel, potential first-in-class investigational bispecific antibody, ivonescimab, was presented at the 2024 European Society for Medical Oncology Annual Meeting (ESMO 2024) in Barcelona, Spain, including two presentations and one poster featuring updated ivonescimab data in advanced triple-negative breast cancer (TNBC), recurrent / metastatic head and neck squamou.

Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024

Summit's Ivonescimab bested Keytruda in a phase 3 trial for lung cancer patients with the PD-L1 gene. Following the early-week stock spike, Summit raised over $200 million from investors.

Why Summit Therapeutics Skyrocketed 123% This Week

Several accredited investors entered an agreement to buy roughly $235 million of Summit Therapeutics stock. These investors included several of the biopharmaceutical company's executives and board members.

Why Summit Therapeutics Stock Is Soaring Again Today

Summit Therapeutics stock rocketed again Thursday — adding onto an 85% gain this week — after raising $235 million in a private placement.

Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale

Summit Therapeutics Inc. NASDAQ: SMMT has seen a meteoric rise this month, surging over 106% after releasing positive clinical trial results for its experimental cancer therapy. Year-to-date, the stock is up a staggering 769%.

Summit Therapeutics Surges on Trial Results: Time to Buy?

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Company accepted offers from multiple leading biotech institutional and individual investors to purchase an aggregate of approximately 10.35 million shares of the Company's common stock at $22.70 per share, the closing price on Wednesday, September 11, 2024, for aggregate gross proceeds to the Company of approximately $235 million. The capital raise was completed without b.

Summit Therapeutics Raises $235 Million

Data from a late-stage study shows that SMMT's experimental antibody beat Keytruda in a head-to-head setting in treating certain patients with NSCLC.

Summit Hits Record High on Lung Cancer Drug Topping Merck's Keytruda

Ivonescimab is a bispecific antibody that targets PD-1 and VEGF to treat lung cancer. In a phase 3 trial, patients treated with ivonescimab were 49% less likely to experience their disease worsening than patients treated with Keytruda.

Is Summit Therapeutics a Buy Now?

Summit's lung cancer treatment Ivonescimab outperformed Merck's Keytruda in a Phase III trial. The data were even better than anticipated.

Why Summit Therapeutics Rocketed Over 60% Today

Summit's and Akeso's ivonescimab outperformed Merck's Keytruda in a phase 3 trial for first-line advanced NSCLC, showing significant clinical benefits. Ivonescimab's success against Keytruda in NSCLC positions Summit to capture a large market share in the multibillion-dollar NSCLC indication. Positive trial results opens expansion opportunities for ivonescimab in first-line PD-L1 high advanced NSCLC and eventually other cancer types.

Summit Therapeutics: Positive Data Leads To Targeting Of Other NSCLC Subpopulation

Shares of Summit Therapeutics (SMMT) skyrocketed Monday, rising to an all-time high after the biotech announced positive results from a late-stage trial of its experimental lung cancer treatment.

Lung Cancer Drug Trial News Has Summit Therapeutics Stock Up 40% Today

Shares of Summit Therapeutics Inc. jumped more than 30% premarket on Monday after the biotech company released late-stage trial data showing that its experimental lung-cancer treatment topped Merck's blockbuster Keytruda.

Summit Therapeutics' stock pops as lung-cancer treatment beats Merck blockbuster in late-stage trial

Summit shares jumped Monday after positive late-stage indications vs. Merck's Keytruda.

Biotech Stocks: Lung Cancer Treatment Outflanks Merck's Keytruda

Sunday, Summit Therapeutics Inc. SMMT released data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab conducted in China, sponsored by collaboration partner Akeso, Inc.

Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced data from the primary analysis of the Phase III HARMONi-2 trial featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented this morning as part of the Presidential Symposium at the International Association for the Study of Lung Cancer's (IASLC) 2024 World Conference on Lung Cancer (WCLC 2024) in San Diego, California. The.

Ivonescimab Monotherapy Reduced the Risk of Disease Progression or Death by 49% Compared to Pembrolizumab Monotherapy in First-Line Treatment of Patients with PD-L1 Positive Advanced NSCLC in China

News for Summit Therapeutics Stock (SMMT)